You are here:
03 April 2020 / deal

Loyens & Loeff advised Karo Pharma AB on Swiss aspects of the acquisition of all shares in Hygis SA

Hygis SA is a Swiss distributing company with exclusive distribution rights to Karo Pharma’s brands MultiGyn and MultiMam. This acquisition will further strengthen Karo Pharma’s direct presence in the DACH region.

How to structure a joint venture in real estate?

Karo Pharma is a pharmaceutical company founded in 1987 specialized in sales and marketing of prescription pharmaceuticals and over-the-counter products sold in pharmacies and retail. Karo Pharma is listed on Nasdaq Stockholm Mid Cap.

Loyens & Loeff advised Karo Pharma in the transaction with a team led by Marco Toni and consisted of Fabian Sutter, Valérie Schrämli and Renate Loretan-Bührle.

Life Sciences Bit Tightened Swiss regulatory requirements in relation to international pharmaceuticals trading

Life Sciences Bit: Tightened Swiss regulatory requirements

Swiss wholesale license holder must tighten their audit practices towards suppliers from countries outside of the EU. read more
Due Diligence For Swiss CBD Companies

Due Diligence for Swiss CBD Companies

Switzerland has proven to provide for attractive conditions for businesses involved in the production and distribution of cannabidiol (CBD) products. read more

Webinar on legal aspects of scaling up your business and attracting external funding

If you are an entrepreneur in the life sciences, pharma or healthcare industry and you aim to attract external funding to develop and grow your business or you... read more